Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Summary

In summary, there is a high medical need for patients suffering from recurrent/progressive PCNSL. Targeting the PD-1 pathway may represent a very promising novel approach for the treatment of these patients.

Timeline

Start

2016-06

Primary completion

2018-06

Completion

2019-06

Drugs

Indications